Most patients with HAE experience angioedema attacks because they lack functioning C1-INH. BERINERT replaces missing or dysfunctional C1-INH through an intravenous infusion, which quickly restores their C1-INH levels.
C1-INH inactivates C1, thereby stopping the production of proteolytic fragments and inflammation-inducing complexes.
C1-INH inhibits plasmin, thus inhibiting fibrin degradation.
C1-INH prevents the conversion of prekallikrein to kallikrein—and the subsequent formation of bradykinin.
C1-INH inhibits Factors XIIa and XIa.
Watch a presentation about the physiological function of C1-INH and how C1-INH replacement therapy treats the root cause of HAE attacks.
A single dose of BERINERT IV provides a rapid increase in C1-INH levels*
*In a prospective, randomized, open-label, crossover study, 23 subjects with mild or moderate HAE received a single dose of BERINERT (1000 units) IV or SC during an attack-free interval.5
|AUC(0–t) (hr x IU/mL)‡||12.8||9.78|
|Volume at steady state (mL/kg)||35.4||38.8|
|Mean residence time (hr)||26.4||24.0|
†Adjusted for baseline.
‡Based on 15 IU/kg dose.
§Age range: 6–13 years.